REFERENCES

1. Rontgen WG. Ueber eine neue Art von Strahlen. Sitzungsberichte der physikalisch-medicinischen Gesellschaft zu Wurzberg, 1895. Sitzung 1895;30:132-31.

2. Grubbe EH. Priority in the therapeutic use of X-rays.

3. Allen CW Radiotherapy, Photography and Radium High Frequency Currents. London: Kimpton; 1905.

4. Lederman M. The early history of radiotherapy: 1895-1939. IJROBP 1981;7:639-48.

5. Robison RF. Theraceformegavoltage. Acta Oncol 1995;34:1055-74.

6. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry 1983;46:797-803.

7. Farmer F, Fowler J, Haggith JW Megavoltage treatment planning and the use of zeroradiography. Br J Radiol 1963;36:426-35.

8. Haie-Meder C, Mazeron R, Magne N. Clinical evidence on PET- CT for radiation therapy planning in cervix and endometrial cancer. Radiother Oncol 2010;96:351-55.

9. Xu-Welliver M, Yuh W, Fielding J, et al. Imaging across the life span: innovations in imaging and therapy for gynecologic cancer. Radiographics 2014;34:1062-81.

10. Small W, Mell L, Anderson P, et al. Consensus guidelines for de­lineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cer­vical cancer. Radiother Oncol 2008;71:428-34.

11. Lim K, Small W, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Radiother Oncol 2011;79:348-55.

12. Lim K, Erikson B, Jurgenliemk-Schultz I, et al. Variability in clin­ical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. Pract Radiat Oncol 2015;5:e557-65.

13. Gay H, Barthold H, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group Consensus Panel Atlas.

14. Peacock CM. A system for planning and rotational delivery of in­tensity-modulated fields. Int J Imag Sys Tech 1995;6:56-65.

15. Webb S. Optimisation of conformal radiotherapy dose distribu­tion by simulated annealing. Phys Med Biol 1989:34:1349.

16. Brahme A. Design principles and clinical possibilities with a new generation of radiation therapy equipment: a review. Acta Oncol 1987;26:403-12.

17. Bortfeld T, Kahler D, Waldron T, Boyer A. X-ray field compensa­tion with multileaf collimators. Radiother Oncol 1994;28:723-30.

18. Roeske J, Lujan A, Rotmensch J, Waggoner S, Yamada D, Mundt A. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Radiother Oncol 2000;48:1613-21.

19. Mundt A, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic maIignancies. Radiother Oncol 2002;52:1330-37.

20. Mundt A, Mell L, Roeske J. Preliminary analysis of chronic gastrointestional toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Radiother Oncol 2003;56:1354-60.

21. Jhingran A, Winter K, Portelance L, et al. A phase II study of in­tensity modulated radiation therapy to the pelvis for postoper­ative patients with endometrial carcinoma: Radiation Therapy Oncology Group Trial 0418. Radiother Oncol 2012;84:e23-28.

22. Klopp A, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gyneco­logic cancer. Radiother Oncol 2013;86:83-90.

23. Beriwal S, Heron D, Kim H, et al. Intensity-modulated radio­therapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Radiother Oncol 2006;64:1395-400.

24. Jaffray D, Drake D. A radiographic and tomographic imaging system integrated into a medical linear accelerator for localization of bone and soft-tissue targets. Radiother Oncol 1999;45:773-89.

25. Taylor A, Powell M.

26. Langerak T, Mens J, Quint S, et al. Cervix motion in 50 cervical cancer patients assessed by daily cone beam computed tomographic imaging of a new type of marker. Radiother Oncol 2015;93:532-39.

27. Van de Bunt L, van der Heide U, Ketelaars M, de Kort G, Jurgenliemk-Schulz I. Conventional, conformal, and intensity- modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: the impact of tumor regression. Radiother Oncol 2006;64:189-96.

28. Chan P, Dinniwell R, Haider M, et al. Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-mri point-of-interest study. Radiother Oncol 2008;70:1507-15.

29. Beadle B, Jhingran A, Salehpour M, Sam M, Iyer R, Eifel P. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Radiother Oncol 2009;73:235-41.

30. Kerkhof E, Raaymakers B, van der Heide U, van de Bunt L, Jurgenliemk-Schultz I, Lagendijk J. Online MRI guidance for healthy tissue sparing in patients with cervical cancer: an IMRT planning study. Radiother Oncol 2008;88:241-49.

31. Oh S, Stewart J, Moseley J, et al. Hybrid adaptive radiotherapy with on-line MRI in cervix cancer IMRT. Radiother Oncol 2014;110:323-28.

32. Stewart J, Lim K, Kelly V, et al. Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. Radiother Oncol 2010;78:350-58.

33. Lim K, Stewart J, Kelly V, et al. Dosimetrically triggered adaptive intensity modulated radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2014;90:147-54.

34. Song W, Huh S, Liang Y, et al. Dosimetric comparison study be­tween intensity modulated radiation therapy and three-dimen­sional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer.

35. Milby A, Both S, Ingram M, Lin L. Dosimetric comparison of combined intensity-modulated radiotherapy (IMRT) and proton therapy versus IMRT alone for pelvic and para-aortic radio­therapy in gynecologic malignancies. Int J Radiat Oncol Biol Phys 2012;82:e477-84.

16. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has inde­pendent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-87.

37. Fyles A, Milosevic M, Wong R, et al. Oxygenation predicts ra­diation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.

38. Nakano T, Suzuki Y, Ohno T, et al. Carbon beam therapy over­comes the radiation resistance of uterine cervical cancer origin­ating from hypoxia. Clin Can Res 2006;12:2185.

39. Janeway HH, Baringer BS, Failla G. Radium Therapy in Cancer at the Memorial Hospital. New York: Paul Hoeber Publishers; 1917.

40. Fokdal L, et al. Image guided adaptive brachytherapy with com­bined intracavitary and interstitial technique improves the thera­peutic ratio in locally advanced cervical cancer: analysis from the retroEMBRACE study. Radiother Oncol 2016;120:434-40.

41. Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV Radiother Oncol 2005;74:235-45.

42. Almond P, Biggs P, Coursey B, et al. AAPMs TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys 1999;26:1847-70.

43. International Atomic Energy Agency (IAEA). Absorbed Dose Determination in External Beam Radiotherapy. Technical Report Series No. 398. Vienna: IAEA; 2000.

44. Valentin J (ed). The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 2007;37:1-332.

45. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC).

46. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Radiother Oncol 2013;87:111-19.

47. Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: mo­lecular basis and therapeutic perspectives. Cancer Treat Rev 2015;41:844-52.

48. Petrelli F, Sarti E, Barni S. Predictive value of human papilloma­virus in oropharyngeal carcinoma treated with radiotherapy: an updated systematic review and meta-analysis of 30 trials. Head Neck 2014;36:750-59.

49. Small W Jr, Strauss JB, Jhingran A, et al. ACR Appropriateness Criteria® definitive therapy for early-stage cervical cancer. Am J Clin Oncol 2012;35:399-405.

50. Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 2015;4:CD010260.

51. Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al. ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. Radiother Oncol 2011;81:609-14.

52. DiSilvestro PA, Ali S, Craighead PS, et al. Phase III random­ized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol 2014;32:458-64.

53. Croke J, Leung E, Fyles A. Gynecological malignancies. In: Nieder C, Langendijk J (eds), Re-Irradiation: New Frontiers, pp. 267-280. Heidelberg: Springer; 2011.

54. Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer Cochrane Database Syst Rev 2012;5:CD007583.

55.

56. Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC study group. Lancet 2000;355:1404-11.

57. Keys, HM, Roberts JA, Brunetto VL, et al. A phase III trial of sur­gery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51.

58. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial

59. Creutzberg CL, Wim LJ, Van Putten CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endomet­rial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma trial. J Clin Oncol 2004:22:1234-41.

60. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole -abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24: 36-44.

61. Klopp AH, Jhingran A, Ramondetta L, et al. Node-positive adeno­carcinoma of the endometrium: outcome and patterns of recur­rence with and without external beam irradiation. Gynecol Oncol 2009;115:6-11.

62. Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recur­rence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for ad­juvant radiation therapy. Radiother Oncol 2001;50:1145-53.

63. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a ran­domized trial. Br J Cancer 2006;95:266-71.

64. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomized studies. Eur J Cancer 2010;46: 2422-31.

65. Klopp A, Smith BD, Alektiar K, et al. The role ofpost-operative ra­diation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence based guide­line. Pract Radiat Oncol 2014:4:137-44.

66. Rouanet P, Dubois JB, Gely S, et al. Exclusive radiation therapy in endometrial carcinoma. Radiother Oncol 1993;26:223-28.

67. Lin, LL, Grigsby PW, Powell MA, Mutch DG. Definitive radio­therapy in the management of isolated vaginal recurrences of endometrial cancer. Radiother Oncol 2005;63:500-504.

68. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for pa­tients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Radiother Oncol 2003;56:1366-72.

69. Lee LJ, Jhingran A, Kidd E, et al. ACR appropriateness Criteria management of vaginal cancer. Oncology (Williston Park) 2013;27:1166-73.

70. Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Radiother Oncol 2005;62:138-47.

71. Kirkbride P, Fyles A, Rawlings GA, et al. Carcinoma of the va­gina—experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol 1995;56:435-43.

72. Samant R, Lau B, Choan E, Le T, Tam T. Primary vaginal cancer treated with concurrent chemoradiation using cis-platinum. Radiother Oncol 2007;69:746-50.

73. Otton GR, Nicklin JL, Dickie GJ, et al. Early-stage vaginal carcinoma—an analysis of 70 patients. Int J Gynecol Cancer 2004;14:304-10.

74. Benedetti Panici P, Bellati F, Plotti F, et al. Neoadjuvant chemo­therapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecol Oncol 2008;111:307-11.

75. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012;12:CD007406.

76. Perez CA, Grigsby PW, Garipagaoglu M, Mutch DG, Lockett MA. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Radiother Oncol 1999;44:37-45.

77. Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-patho­logic variables predictive of local recurrence in squamous cell car­cinoma of the vulva. Gynecol Oncol 1990;38:309-14.

78. Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 1997;38:381-89.

79. Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009;114:537-46.

80. Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:79-85.

81. Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gyneco­logic oncology group study. Gynecol Oncol 2012;124:529-33.

82. Gaffney DK, King B, Viswanathan AN, et al. Consensus recom­mendations for radiotherapy contouring and treatment of vulvar carcinoma. Int J Radiat Oncol Biol Phys 2016;95:1191-200.

83. Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-b ased outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradi­ation. J Clin Oncol 2012;30:1656-62.

84. Kumar A, Le N, Tinker AV, Santos JL, Parsons C, Hoskins PJ. Early-stage endometrioid ovarian carcinoma: popula­tion-based outcomes in British Columbia. Int J Gynecol Cancer 2014;24:1401-405.

85. Swenerton KD, Santos JL, Gilks CB, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol 2011;22:341-47.

86. Thomas G. Revisiting the role ofradiation treatment for non- serous subtypes of epithelial ovarian cancer. Presented at the American Society of Clinical Oncology. Meeting, 1 June 2013. Available at: https://meetinglibrary.asco.org/record/79711/edbook.